512 related articles for article (PubMed ID: 32937002)
1. Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel.
Escuriola-Ettingshausen C; Auerswald G; Königs C; Kurnik K; Scholz U; Klamroth R; Oldenburg J
Haemophilia; 2021 May; 27(3):e305-e313. PubMed ID: 32937002
[TBL] [Abstract][Full Text] [Related]
2. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee.
Collins PW; Liesner R; Makris M; Talks K; Chowdary P; Chalmers E; Hall G; Riddell A; Percy CL; Hay CR; Hart DP
Haemophilia; 2018 May; 24(3):344-347. PubMed ID: 30070072
[TBL] [Abstract][Full Text] [Related]
3. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.
Batsuli G; Zimowski KL; Tickle K; Meeks SL; Sidonio RF
Haemophilia; 2019 Sep; 25(5):789-796. PubMed ID: 31373431
[TBL] [Abstract][Full Text] [Related]
4. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.
Gelbenegger G; Schoergenhofer C; Knoebl P; Jilma B
Thromb Haemost; 2020 Oct; 120(10):1357-1370. PubMed ID: 32717759
[TBL] [Abstract][Full Text] [Related]
5. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
Jenkins PV; Bowyer A; Burgess C; Gray E; Kitchen S; Murphy P; Platton S; Riddell A; Chowdary P; Lester W
Haemophilia; 2020 Jan; 26(1):151-155. PubMed ID: 31859415
[TBL] [Abstract][Full Text] [Related]
6. Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A.
Holstein K; Albisetti M; Bidlingmaier C; Halimeh S; Heine S; Klamroth R; Königs C; Kurnik K; Male C; Oldenburg J; Streif W; Wermes C; Escuriola-Ettingshausen C;
Hamostaseologie; 2020 Dec; 40(5):561-571. PubMed ID: 32588417
[TBL] [Abstract][Full Text] [Related]
7. Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery.
Jiménez-Yuste V; Rodríguez-Merchán EC; Matsushita T; Holme PA
Haemophilia; 2021 Jul; 27(4):519-530. PubMed ID: 33988293
[TBL] [Abstract][Full Text] [Related]
8. Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.
Coppola A; Castaman G; Santoro RC; Mancuso ME; Franchini M; Marino R; Rivolta GF; Santoro C; Zanon E; Sciacovelli L; Manca S; Lubrano R; Golato M; Tripodi A; Rocino A;
Haemophilia; 2020 Nov; 26(6):937-945. PubMed ID: 33094880
[TBL] [Abstract][Full Text] [Related]
9. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
[No Abstract] [Full Text] [Related]
10. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors.
Carcao M; Mancuso ME; Young G; Jiménez-Yuste V
Expert Rev Hematol; 2021 Feb; 14(2):143-148. PubMed ID: 33499681
[No Abstract] [Full Text] [Related]
11. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.
Castaman G; Santoro C; Coppola A; Mancuso ME; Santoro RC; Bernardini S; Pugliese FR; Lubrano R; Golato M; Tripodi A; Rocino A; Santagostino E; ; Biasoli C; Borchiellini A; Catalano A; Contino L; Coluccia A; Cultrera D; De Cristofaro R; Di Minno G; Fabbri A; Franchini M; Gamba G; Giuffrida AC; Gresele P; Giampaolo A; Hassan HJ; Luciani M; Marchesini E; Marino R; Mazzucconi MG; Molinari AC; Morfini M; Notarangelo LD; Peccarisi L; Peyvandi F; Pollio B; Rivolta GF; Ruggieri MP; Sargentini V; Schiavoni M; Sciacovelli L; Serino ML; Siragusa S; Tagliaferri A; Testa S; Tosetto A; Zampogna S; Zanon E
Blood Transfus; 2020 Mar; 18(2):143-151. PubMed ID: 31657709
[TBL] [Abstract][Full Text] [Related]
12. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the safety of emicizumab in patients with hemophilia A.
Langer AL; Etra A; Aledort L
Expert Opin Drug Saf; 2018 Dec; 17(12):1233-1237. PubMed ID: 30462521
[TBL] [Abstract][Full Text] [Related]
14. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
Mahlangu JN
BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
[TBL] [Abstract][Full Text] [Related]
15. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.
Carcao M; Escuriola-Ettingshausen C; Santagostino E; Oldenburg J; Liesner R; Nolan B; Bátorová A; Haya S; Young G;
Haemophilia; 2019 Jul; 25(4):676-684. PubMed ID: 31033112
[TBL] [Abstract][Full Text] [Related]
16. Emicizumab: A Review in Haemophilia A.
Blair HA
Drugs; 2019 Oct; 79(15):1697-1707. PubMed ID: 31542880
[TBL] [Abstract][Full Text] [Related]
17. Emicizumab for the treatment of haemophilia A: a narrative review.
Franchini M; Marano G; Pati I; Candura F; Profili S; Veropalumbo E; Masiello F; Catalano L; Piccinini V; Vaglio S; Pupella S; Liumbruno GM
Blood Transfus; 2019 May; 17(3):223-228. PubMed ID: 31246563
[TBL] [Abstract][Full Text] [Related]
18. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US.
Lewandowska M; Randall N; Bakeer N; Maahs J; Sagar J; Greist A; Shapiro AD
Haemophilia; 2021 Jan; 27(1):90-99. PubMed ID: 33245841
[TBL] [Abstract][Full Text] [Related]
19. Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms.
Lillicrap D; Fijnvandraat K; Young G; Mancuso ME
Expert Rev Hematol; 2020 Apr; 13(4):313-321. PubMed ID: 32186928
[No Abstract] [Full Text] [Related]
20. Haemophilia in the era of novel therapies: Where do inhibitors feature in the new landscape?
Meeks SL; Zimowski KL
Haemophilia; 2024 Apr; 30 Suppl 3():95-102. PubMed ID: 38539060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
